AstraZeneca Reports Updated Data from the P-III (ADJUVANT BR.31) Study of Imfinzi to Treat Non-Small Cell Lung Cancer
Shots:
- The P-III (ADJUVANT BR.31) study, funded by the Canadian Cancer Trials Group, assessed adj. Imfinzi vs PBO among Stage IB (≥4cm), II or IIIA NSCLC patients (n=1,415) post complete tumor resection, with/without adj. CT
- Study did not reach its 1EP of DFS specifically in patients with PD-L1-expressing tumors. The safety profile aligned with the previous studies without any new safety outcomes; data will be highlighted at future conferences
- In addition, Imfinzi is further being assessed under the PACIFIC-4 study alone or in combinations for inoperable or unresected Stage I-II NSCLC as well as PACIFIC-5, 8 and 9 for Stage III NSCLC
Ref: AstraZeneca | Image: AstraZeneca
Related News:- AstraZeneca’s Imfinzi Combined with Chemotherapy Gains the US FDA’s Approval to Treat Endometrial Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
